Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diagnamed HoldingsDGNMF +3.24% EV-to-EBITDA is -3.85 as of Aug. 04, 2026. The stock has 1 warning sign investors should review. Among 508 Healthcare Providers & Services companies, Diagnamed Holdings ranks worse than 196850.2% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Diagnamed Holdings's enterprise value is $5.12 Mil.
Diagnamed Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.33 Mil. Therefore, Diagnamed Holdings's EV-to-EBITDA for today is -3.85.
The historical rank and industry rank for Diagnamed Holdings's EV-to-EBITDA or its related term are showing as below:
DGNMF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.85 Med: 0 Max: 0
Current: -3.85
DGNMF's EV-to-EBITDA is ranked worse than 100% of 508
companies
in the Healthcare Providers & Services industry
Industry Median: 11.02
vs DGNMF: -3.85
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Diagnamed Holdings's PE Ratio (TTM) for today is calculated as:
Diagnamed Holdings's share price for today is $0.035.
Diagnamed Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.014.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Diagnamed Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Diagnamed Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diagnamed Holdings EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diagnamed Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Diagnamed Holdings's EV-to-EBITDA falls into.
Diagnamed Holdings's current Enterprise Value is $5.12 Mil.
Diagnamed Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.33 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diagnamed Holdings (DGNMF) has a EV-to-EBITDA of -3.85 as of Aug. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Diagnamed Holdings. According to the industry distribution chart, Diagnamed Holdings ranks #999999 out of 508 companies in the Healthcare Providers & Services industry.
Is Diagnamed Holdings' EV-to-EBITDA too high?
Diagnamed Holdings' current EV-to-EBITDA is -3.85. Based on the distribution chart, Diagnamed Holdings ranks #999999 out of 508 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does Diagnamed Holdings' EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diagnamed Holdings ranks #999999 out of 508 companies for EV-to-EBITDA. This places Diagnamed Holdings in the lower half of its industry. The industry median EV-to-EBITDA is 11.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.02, based on 508 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Diagnamed Holdings. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diagnamed Holdings's current EV-to-EBITDA is -3.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnamed Holdings stock overvalued right now?
Diagnamed Holdings (DGNMF) has a current EV-to-EBITDA of -3.85. The current EV-to-EBITDA is -3.85. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Diagnamed Holdings (DGNMF), the current EV-to-EBITDA is -3.85 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Diagnamed Holdings Corp is engaged in developing a platform of software-based prescription digital therapeutic products (PDT Products) with the potential to improve early detection of neurological disorders, overall patient health and lower healthcare costs. Its products include, CERVAI which is a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders. It is also investigating other technological applications such as BrainAge and BrainTremor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DGNMF has been successfully added to your 
